Trial Profile
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 12 Jun 2025
Price :
$35
*
At a glance
- Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Cobimetinib (Primary) ; Entrectinib (Primary) ; Vemurafenib (Primary) ; Bevacizumab; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms B-FAST
- Sponsors Roche
Most Recent Events
- 30 Apr 2025 Results assessing efficacy of targeted therapies in patients with unresectable, advanced or metastatic NSCLC selected based on the presence of oncogenic somatic mutations or a positive bTMB score, presented at the 116th Annual Meeting of the American Association for Cancer Research.
- 01 Nov 2024 Status changed from recruiting to active, no longer recruiting.
- 01 Jul 2024 According to Results published in the Nature Medicine Primary endpoint (Cohort D: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on the RECIST v1.1)has been met.